Results 11 to 20 of about 36,553 (257)

Assessing the immunogenicity and toxicity of the AFPL1-conjugate nicotine vaccine using heterologous and homologous vaccination routes. [PDF]

PLoS One, 2019
Malgré les risques accrus de cancers et de maladies cardiovasculaires, le tabagisme continue d'être répandu dans la population en grande partie en raison de la nature addictive de la nicotine. Les vaccins à la nicotine sont une alternative attrayante aux options actuelles de sevrage tabagique, mais ils n'ont pas encore eu suffisamment de succès dans ...
Fraleigh NL, Oliva R, Lewicky JD, Martel AL, Acevedo R, Dagmar GR, Le HT.   +6 more
europepmc   +5 more sources

Evolution of infectious bronchitis virus in the field after homologous vaccination introduction. [PDF]

Vet Res, 2019
AbstractDespite the fact that vaccine resistance has been typically considered a rare phenomenon, some episodes of vaccine failure have been reported with increasing frequency in intensively-raised livestock. Infectious bronchitis virus (IBV) is a widespread avian coronavirus, whose control relies mainly on extensive vaccine administration ...
Franzo G, Legnardi M, Tucciarone CM, Drigo M, Martini M, Cecchinato M.   +5 more
europepmc   +7 more sources

Immunogenicity and Durability of Antibody Responses to Homologous and Heterologous Vaccinations with BNT162b2 and ChAdOx1 Vaccines for COVID-19

Vaccines, 2022
During the COVID-19 pandemic, vaccines were developed based on various platform technologies and were approved for emergency use. However, the comparative analysis of immunogenicity and durability of vaccine-induced antibody responses depending on ...
Dong-In Kim, Seo Jin Lee, Soonju Park, Paul Kim, Sun Min Lee, Nakyung Lee, David Shum, Dong Ho Kim, Eui Ho Kim   +8 more
doaj   +3 more sources

Broadening SARS-CoV-2 Immunity by Combining ORFV and Protein-Based Vaccines [PDF]

Vaccines
Background: Emerging immune-evasive viral variants threaten the efficacy of current vaccines, underscoring the need for strategies that elicit broad and durable protection.
Alena Reguzova, Melanie Müller, Madeleine Fandrich, Alex Dulovic, Ralf Amann   +4 more
doaj   +2 more sources

Homologous and Heterologous Covid-19 Booster Vaccinations

New England Journal of Medicine, 2022
Although the three vaccines against coronavirus disease 2019 (Covid-19) that have received emergency use authorization in the United States are highly effective, breakthrough infections are occurring. Data are needed on the serial use of homologous boosters (same as the primary vaccine) and heterologous boosters (different from the primary vaccine) in ...
Robert L. Atmar, Kirsten E. Lyke, Meagan E. Deming, Lisa A. Jackson, Angela R. Branche, Hana M. El Sahly, Christina A. Rostad, Judith M. Martin, Christine Johnston, Richard E. Rupp, Mark J. Mulligan, Rebecca C. Brady, Robert W. Frenck, Martín Bäcker, Angelica C. Kottkamp, Tara M. Babu, Kumaravel Rajakumar, Srilatha Edupuganti, David Dobrzynski, Rhea N. Coler, Christine M. Posavad, Janet I. Archer, Sonja Crandon, Seema U. Nayak, Daniel Szydlo, Jillian A. Zemanek, Clara P. Dominguez Islas, Elizabeth R. Brown, Mehul S. Suthar, M. Juliana McElrath, Adrian B. McDermott, Sarah E. O’Connell, David C. Montefiori, Amanda Eaton, Kathleen M. Neuzil, David S. Stephens, Paul C. Roberts, John H. Beigel   +37 more
openaire   +2 more sources

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts

JAMA Network Open, 2022
Importance: Antibody responses elicited by current messenger RNA (mRNA) COVID-19 vaccines decline rapidly and require repeated boosting. Objective: To evaluate the immunogenicity and durability of heterologous and homologous prime-boost regimens involving the adenovirus vector vaccine Ad26.COV2.S and the mRNA vaccine BNT162b2.
Tan, C. Sabrina, Collier, Ai-ris Y., Yu, Jingyou, Liu, Jinyan, Chandrashekar, Abishek, McMahan, Katherine, Jacob-Dolan, Catherine, He, Xuan, Roy, Vicky, Hauser, Blake M., Munt, Jennifer E., Mallory, Michael L., Mattocks, Melissa, Powers, John M., Meganck, Rita M., Rowe, Marjorie, Hemond, Rachel, Bondzie, Esther A., Jaegle, Kate H., Baric, Ralph S., Schmidt, Aaron G., Alter, Galit, Le Gars, Mathieu, Sadoff, Jerald, Barouch, Dan H.   +24 more
openaire   +2 more sources

Experiments with a homologous, inactivated canine parvovirus vaccine in vaccination programmes for dogs [PDF]

Veterinary Quarterly, 1982
The significance of canine parvovirus (CPV) infections as a permanent threat susceptible dogs, in particular pups, made the authors develop three liquid homologous inactivated adjuvant CPV vaccines that were compatible with existing canine vaccines and could be incorporated in current vaccination programmes.
J H, Wilson, W M, Hermann-Dekkers
openaire   +2 more sources

Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people [PDF]

Immunity & Ageing, 2021
Abstract Background Several SARS-CoV-2 vaccines have shown clinical efficacy against Covid-19 infection but there remains uncertainty about the immune responses elicited by different regimens.
Helen Parry, Rachel Bruton, Christine Stephens, Kevin Brown, Gayatri Amirthalingam, Ashley Otter, Bassam Hallis, Jianmin Zuo, Paul Moss   +8 more
openaire   +3 more sources

Intradermal vaccination of live attenuated influenza vaccine protects mice against homologous and heterologous influenza challenges [PDF]

npj Vaccines, 2021
AbstractWe previously developed a temperature-sensitive, and NS1 gene deleted live attenuated influenza vaccine (DelNS1-LAIV) and demonstrated its potent protective efficacy in intranasally vaccinated mice. Here we investigated whether intradermal (i.d.) vaccination induces protective immunity.
Andrew Chak-Yiu Lee, Anna Jinxia Zhang, Can Li, Yanxia Chen, Feifei Liu, Yan Zhao, Hin Chu, Carol Ho-Yan Fong, Pui Wang, Siu-Ying Lau, Kelvin Kai-Wang To, Honglin Chen, Kwok-Yung Yuen   +12 more
openaire   +3 more sources

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection

Emerging Microbes and Infections, 2022
Given emerging evidence of immune escape in the SARS-CoV-2 Omicron viral variant, and its dominance, effectiveness of heterologous and homologous boosting schedules commonly used in low-to-middle income countries needs to be re-evaluated.
Jing Lian Suah, Boon Hwa Tng, Peter Seah Keng Tok, Masliyana Husin, Thevesh Thevananthan, Kalaiarasu M. Peariasamy, Sheamini Sivasampu   +6 more
doaj   +1 more source